Conversation with Novo Nordisk Pharma Japan President and Representative Director Kasper Bødker Mejlvang
Langue(s) de l'événement
English
Tarif :
Member 4,500 jpy
Non-member 8,500 jpy
Event registration is only complete upon payment.
Any cancellation after the deadline or no-show will be charged.
A 1,000JPY late fee will be applied to registrations made past the deadline.
L'événement est terminé.
Novo Nordisk aims to defeat serious chronic disease, both through effective prevention as well as the most innovative treatments which enable people to live their lives on their own terms. The company was established 100 years ago by a physician trying to save the life of his wife who was diagnosed with diabetes. Since then, they have entered into adjacent disease areas, lately with an innovative treatment for obesity which has taken the world by storm.
What has made Novo Nordisk enter into the field of obesity, a condition associated with stigma and controversy? What does it take to compellingly make the case for Japanese regulators to approve a non-Japanese pharmaceutical product? How do you convince a medical community, a portion of whose practitioners often view obesity as a character and behavioral discipline issue, rather than what obesity really is—an eminently treatable disease? How do you manage rapid growth of and demand for a medical product with widespread appeal in an ethical manner while protecting the best interests of the people it is meant to help?
If you would like to know the answers to these questions and more, come and ask our featured guest Novo Nordisk Japan President Kasper Bødker Mejlvang yourself?
Entrepreneur Committee leader Steven Bleistein start a conversation with Kasper and then invite the audience to join in and ask their own questions, providing ample time so you can ask yours. There will be no slides, speeches, or presentations—just provocative, unscripted conversation.
If you lead or work in a business in Japan, whether health-related, highly regulated, or not, this is an event not to be missed.
NOTE: This event is off-the-record.
<Time Schedule>
11:45 Opening Doors
12:00 Networking Time
12:15 Lunch
12:35 Opening Remarks
12:40 Onstage Conversation
13:05 Audience Questions
13:30 Closing Remarks
14:00 End of the event
Intervenant(s)
Contact
reservation@ccifj.or.jp
03-4500-6529
Modalités d'accès
Conversation with Novo Nordisk Pharma Japan President and Representative Director Kasper Bødker Mejlvang
L'événement est terminé.